IN-ARMOR Consortium Strategize for Upcoming Project Review and Clinical Transitions

On May 28, 2026, our team joined work package leaders and key representatives from the partners   for the 13th Management Board Meeting (MBM13). This virtual gathering was vital for evaluating recent project milestones and establishing the strategic roadmap for the critical months ahead.

Following the closure of the Second Reporting Period (RP2) in April 2026, the meeting’s primary focus was preparing for the highly anticipated Second Project Review Meeting (PR2) with the European Commission, officially scheduled for the first week of July 2026.

Driving Innovation Against Antimicrobial Resistance

During MBM13, the Management Board reviewed the significant advancements made across all Work Packages (WPs). Biokeralty remains deeply committed to this collaborative effort, which leverages innovative immune system inducers (ISI) to pioneeringly combat antimicrobial resistance (AMR).

Looking Ahead: The 4th Consortium Meeting in Madrid

In addition to technical reviews, the board advanced logistical and strategic planning for the upcoming 4th IN-ARMOR Consortium Meeting. This major in-person event will take place in Madrid, Spain, and will be hosted by our clinical partner, the Madrilenian Health Service (SERMAS). This meeting will serve as an excellent opportunity for the Biokeralty team to align in person with European colleagues, consolidate recent findings, and fine-tune the next phases of development.

At Biokeralty, we are proud to contribute our scientific expertise to Horizon Europe initiatives like IN-ARMOR, fostering healthier societies through cutting-edge translational research.

To stay updated on our research, upcoming milestones, and publications, visit the official website at https://inarmor-project.eu/.